Related Experiment Video
Updated: Feb 24, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism
Alina Steinbach1,2, Jan Winter1, Miriam Reuschenbach3
1Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract:
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and thus T-cell responses against tumor cells. To date, the APM had not been studied systematically in a large array of HPV+ tumor samples. Therefore in this study, systematic expression analysis of the APM was performed on the mRNA and protein level in a comprehensive collection of HPV16+ cell lines. Subsequently, HPV+ cervical tissue samples were examined by immunohistochemistry. ERAP1 (endoplasmic reticulum aminopeptidase 1) was the only APM component consistently altered - namely overexpressed - in HPV16+ tumor cell lines. ERAP1 was also found to be overexpressed in cervical intraepithelial neoplasia and cervical cancer samples; expression levels were increasing with disease stage. On the functional level, the influence of ERAP1 expression levels on HPV16 E7-derived epitope presentation was investigated by mass spectrometry and in cytotoxicity assays with HPV16-specific T-cell lines. ERAP1 overexpression did not cause a complete destruction of any of the HPV epitopes analyzed, however, an influence of ERAP1 overexpression on the presentation levels of certain HPV epitopes could be demonstrated by HPV16-specific CD8+ T-cells. These showed enhanced killing toward HPV16+ CaSki cells whose ERAP1 expression had been attenuated to normal levels. ERAP1 overexpression may thus represent a novel immune evasion mechanism in HPV-induced malignancies, in cases when presentation of clinically relevant epitopes is reduced by overactivity of this peptidase.
Insights
Overexpression of endoplasmic reticulum aminopeptidase 1 (ERAP1) is a novel immune evasion mechanism in human papillomavirus (HPV)-induced cancers. This ERAP1 overexpression impacts T-cell responses by altering tumor antigen presentation, potentially hindering immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor immune evasion is a significant hurdle for effective cancer immunotherapy.
- Human papillomavirus (HPV)-induced cancers employ various immune evasion strategies, including alterations in antigen processing machinery (APM).
- Systematic analysis of APM component expression in HPV-positive tumors was previously lacking.
Purpose of the Study:
- To systematically analyze the expression of APM components in a large cohort of HPV-positive tumor samples.
- To investigate the functional impact of altered APM component expression on T-cell responses against HPV-induced malignancies.
Main Methods:
- Comprehensive mRNA and protein expression analysis of APM components in HPV16-positive cell lines.
- Immunohistochemical examination of APM component expression in HPV-positive cervical tissue samples.
- Mass spectrometry and T-cell cytotoxicity assays to assess the impact of ERAP1 on epitope presentation and T-cell killing.
Main Results:
- Endoplasmic reticulum aminopeptidase 1 (ERAP1) was the sole consistently overexpressed APM component in HPV16-positive tumor cell lines.
- ERAP1 overexpression was observed in cervical intraepithelial neoplasia and cervical cancer, increasing with disease stage.
- ERAP1 overexpression influenced the presentation of certain HPV epitopes and reduced the killing of HPV-positive tumor cells by specific T-cells when ERAP1 levels were normalized.
Conclusions:
- ERAP1 overexpression represents a potential immune evasion mechanism in HPV-induced malignancies.
- Altered ERAP1 activity may reduce the presentation of clinically relevant epitopes, thereby impairing T-cell-mediated anti-tumor immunity.
- Targeting ERAP1 could be a strategy to enhance immunotherapy efficacy in HPV-driven cancers.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Abnormal Proliferation
Non-LTR Retrotransposons
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

